ea0066p8 | Bone | BSPED2019
Sandy Jessica
, Gilbey-Cross Robyn
, Santos Rui
, Sakka Sophia
, Cocca Alessandra
, Morris Mavali
, Massey Jill
, Cheung Moira
Burosumab, monoclonal antibody targeting fibroblast growth factor 23, is now available for clinical use in children with X-linked hypophosphatemia (XLH). We explored the effects of this treatment in a clinical setting, considering biochemistry, growth, deformity, functionality, quality of life, pain and fatigue.Methods: Clinical, biochemical, radiological and questionnaire data were reviewed at 6 and 12 months(m) for 8 children with XLH starting burosuma...